Cell-based diagnostics with applications in hematology, histology, cytology, microbiology, and transplant medicine generated more than $6 billion in revenues last year, and new and innovative enabling technologies are emerging that will propel certain segments of the market forward at double-digit rates, according to a new report released by Kalorama Information (New York).
The new study, Cell-Based Diagnostics: Technologies, Applications, and Markets, 2nd Edition, evaluates the market for both traditional technologies such as hematology, flow cytometry, and traditional stains, as well as increasingly sophisticated molecular techniques and the emerging areas of rare cell event testing, microarrays and beadarrays. These new technologies and digital arrays carry the advantage of being well suited to feed data to software designed to interpret array patterns and create the test result.
These innovations and new methods for genotyping biopsied tissue could revolutionize the treatment of a number of diseases, including diabetes, cancer, and autoimmune and neurodegenerative diseases and could lead the way to an era of individualized patient therapies using techniques such as microarrays, biochips, PCR and in situ hybridization.
Kalorama Information provides independent market research on medical markets.
InSight Health Services changes name
InSight Health Services Holdings (Lake Forest, California) reported the launch of a new brand name, Insight Imaging.
Twenty-two fixed-site centers in California, 10 fixed-site centers in Arizona and two fixed-site centers in Nevada have transitioned to the new Insight Imaging brand. The company intends to complete its Insight Imaging rebranding initiative by mid-2008.
Insight provides diagnostic imaging services.